Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO
Foster & Motley Inc. has acquired a new stake of $2 million in Halozyme Therapeutics (NASDAQ:HALO) during the second quarter, bringing institutional ownership to 97.79%. Halozyme Therapeutics reported strong quarterly results, surpassing EPS and revenue estimates, and provided positive fiscal 2026 EPS guidance, although …